Northwestern Medicine’s Pulmonary Vascular Disease Program has won accreditation as a Comprehensive Care Center by the Pulmonary Hypertension Association (PHA), in recognition of its excellence in diagnosis, research and clinical care of PH patients. To earn the accreditation, the program, which is led by Stuart Rich,…
News
Treatment with aloperine, a traditional Eastern herbal medicine, reduces markers of oxidative stress and improves heart parameters in a pulmonary hypertension (PH) animal model. The results were reported in a study titled “Protective effects of aloperine on monocrotaline-induced pulmonary hypertension in rats,” published in the journal Biomedicine &…
Vasopressor medications can trigger pulmonary hypertension by increasing blood volume rather than constricting blood vessels in the lungs, according to a study. This insight may improve the management of patients treated with vasopressors, particularly those who also have heart disease, researchers said. Vasopressors are used to treat extremely low blood…
Letairis (ambrisentan) was the most efficient, robust therapeutic among endothelin receptor antagonists (ERAs) to treat pulmonary arterial hypertension (PAH), according to a study that compared the drug to three other therapies: Thelin (sitaxsentan), Tracleer (bosentan) and Opsumit (macitentan). The study, “Comparative efficacy and acceptability of endothelin receptor antagonists for…
High levels of a protein called galectin-3 are associated with pulmonary hypertension deaths, according to a study that says targeting the protein could be a way to develop treatments for PH. In fact, the higher the level of the protein, the higher the death rate, the research showed. The study,…
Treatment with 20 mg Revatio (sildenafil) three times a day may be more effective than lower dosages, a clinical trial has concluded. The study, “Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.” appeared in…
Researchers suggest that routine echocardiographic (ECG) screening for pulmonary hypertension (PH) in premature infants might only be needed if certain risk factors are evident. While the proposed approach would identify most children affected and be of help to hospitals, researchers acknowledge that lung hypertension might go undetected in some babies. The change is estimated to…
England’s National Health Service (NHS) has added three treatments to the options it offers patients with rare diseases, one of which is for pulmonary arterial hypertension (PAH). The additions will help up to 145 people annually. NHS England will cover the cost of doctors performing them. NHS approved 19 treatments in…
Infants, newborns and children with pulmonary hypertension (PH) can be safely and effectively treated with phosphodiesterase type 5 (PDE-5) inhibitors, according to a new study. The review study, “Pulmonary Hypertension Therapy and a Systematic Review of Efficacy and Safety of PDE-5 Inhibitors,” appeared in the journal Pediatrics. PDE-5 inhibitors such…
Older age and abnormal oxygen-carbon monoxide blood levels may lead to poorer survival in patients with systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH), compared to patients with idiopathic pulmonary arterial hypertension (IPAH), a new study reports. The study, “Idiopathic And Systemic Sclerosis Associated Pulmonary Arterial Hypertension: A Comparison Of…
Apollo Therapeutics has approved £8.5 million ($10.6 million) to fund four projects, including a small and large molecule discovery program to treat pulmonary arterial hypertension (PAH). Professors Martin Wilkins and Lan Zhao of Imperial College London‘s Department of Medicine will head the PAH program. Both have previously identified a gene called…
The rapid growth of smooth muscle cells in pulmonary arteries causes vasoconstriction and pulmonary arterial hypertension (PAH). Now, researchers found that the same drugs that inhibit cancer cell growth may also be effective in treating PAH. The study, “Inhibition of ubiquitin proteasome function prevents monocrotaline-induced pulmonary arterial…
